This site is intended for health professionals only

Editor’s pick

European Respiratory Society announce COPD winner
European Respiratory Society announce COPD winner
EMCC: BIBF 1120 ‘as effective as bevacizumab’ for colorectal cancer
EMCC: BIBF 1120 ‘as effective as bevacizumab’ for colorectal cancer
EMCC: ‘Unequal access to cancer care no longer tolerated’
EMCC: ‘Unequal access to cancer care no longer tolerated’
EMCC: Everolimus and exemestane ‘improve breast cancer survival rate’
EMCC: Everolimus and exemestane ‘improve breast cancer survival rate’
EMCC: Bisphosphonate ‘effective as bone metastases relief’
EMCC: Bisphosphonate ‘effective as bone metastases relief’
ERS: Moxifloxacin ‘demostrates non-inferiority for COPD’
ERS: Moxifloxacin ‘demostrates non-inferiority for COPD’
ERS: Imatinib ‘significantly improves walking distance’
ERS: Imatinib ‘significantly improves walking distance’
EMCC: Afinitor® ‘more than doubles breast cancer survival’
EMCC: Afinitor® ‘more than doubles breast cancer survival’
EMA recommends Rasitrio® for high blood pressure
EMA recommends Rasitrio® for high blood pressure
Swissmedic accept epilepsy drug perampanel for review
Swissmedic accept epilepsy drug perampanel for review
Tyrosine kinase inhibitor ‘reduces IPF lung decline’
Tyrosine kinase inhibitor ‘reduces IPF lung decline’
Enrolment begins for Phase 3 COPD drug trial
Enrolment begins for Phase 3 COPD drug trial
1 2 3 4 5 6 … 302





Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Subscribe
FOLLOW US

IMPORTANT LINKS

MORE FROM COGORA

© Cogora 2026
Cogora Limited. 1 Giltspur Street, London EC1A 9DD Registered in the United Kingdom. Reg. No. 2147432

Cogora
x